Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 29, 2026

Back to today

Another Haircut with Avy the Barber

SoFi’s stock case hinges on interest rates, tangible book value and private-credit loan sales after its $1.5 billion equity offering.

SOFI $22B
WHAT ARE WE DOING? “Contrarians At The Gate” 3 clicks

From X

@convequity

Convequity on X

The optical engine accounts for over 50% of an optical transceiver's cost, and it contains the most demanding alignment work in the module. For years, engines were built by active alignment: a technician switched on the laser and nudged parts into position until the light coupled. That was workable at 10G, 25G and 100G. At 400G and 800G the tolerances became too tight for manual assembly, and demand driven by AI exceeded what human throughput could supply. $POET's Optical Interposer replaces active alignment with passive assembly. It is a silicon wafer with waveguides and mechanical guides etched into it. Lasers, detectors and electronics are placed on it by automated pick-and-place machines, with nothing powered up during assembly. The parts align passively at the wafer level, much as Lego bricks fit together by their shape. The effect shows up at the transceiver maker. The engine arrives pre-aligned on a standardised substrate, so the remaining assembly looks like conventional electronics manufacturing. Foxconn does that kind of work at high volume, and it was historically locked out of optical transceivers because building them required deep photonic expertise around the engine. Our note's reading is that the interposer takes on the optical complexity so assemblers such as Foxconn, Luxshare, and LITEON do not have to, which helps relieve one of the bottlenecks in optical connectivity for AI clusters.
@KEDM_COM

KEDM.com on X

ProQR Therapeutics $PRQR CEO Daniel de Boer bought $513K across two separate purchases on July 7 and July 9, and a company director bought another $229.5K in late June (real money for a Dutch CEO). PRQR is a small-cap RNA-editing biotech backed by a major pharma partner: Eli Lilly. Their collaboration, running since 2021 and expanded in 2022, could pay ProQR up to $3.75 billion in milestones plus royalties, real validation for a company this size. The balance sheet just got stronger too: ProQR raised roughly $59 million in late June 2026, with Lilly buying in alongside the public offering to keep its stake intact, a vote of confidence from the partner who knows their science best.

Investor Letters

All letters

CoStar: 3Q26 Business Recap

CoStar’s 3Q26 revenue growth slowed to 14% as bookings fell to $37 million, while cost cuts lifted EBIT margin to 8.8%.

CSGP $13B
Speedwell Memos 3 clicks

ServiceNow Q3 FY12/26 Earnings Review

ServiceNow’s Q3 revenue rose 20.5% to $4.11 billion, while non-GAAP EPS missed consensus and fourth-quarter cRPO growth guidance slowed to…

NOW $110B
Cestrian Capital Research 2 clicks

OSS Q3 FY12/26 Earnings Analysis

One Stop Systems grew Q3 continuing-operations revenue 36% to $12.6 million, raised FY2026 revenue guidance to $45 million, and used $11.8…

OSS $129M
Cestrian Capital Research 1 click

Why So Much Copper?

Amphenol and other copper-connectivity suppliers benefit as copper remains essential inside AI racks, where low-voltage, high-current power…

APH $196B
Jimmy's Journal 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 72 of 272

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

285 firms

Sectors

Ordered by how often our editor reaches for them.